BBIO vs. SPY
Compare and contrast key facts about BridgeBio Pharma, Inc. (BBIO) and SPDR S&P 500 ETF (SPY).
SPY is a passively managed fund by State Street that tracks the performance of the S&P 500 Index. It was launched on Jan 22, 1993.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BBIO or SPY.
Key characteristics
| BBIO | SPY | |
|---|---|---|
| YTD Return | -32.90% | 27.04% |
| 1Y Return | 0.07% | 39.75% |
| 3Y Return (Ann) | -19.06% | 10.21% |
| 5Y Return (Ann) | 0.02% | 15.93% |
| Sharpe Ratio | -0.14 | 3.15 |
| Sortino Ratio | 0.18 | 4.19 |
| Omega Ratio | 1.02 | 1.59 |
| Calmar Ratio | -0.11 | 4.60 |
| Martin Ratio | -0.23 | 20.85 |
| Ulcer Index | 33.55% | 1.85% |
| Daily Std Dev | 54.89% | 12.29% |
| Max Drawdown | -92.80% | -55.19% |
| Current Drawdown | -62.56% | 0.00% |
Correlation
The correlation between BBIO and SPY is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
BBIO vs. SPY - Performance Comparison
In the year-to-date period, BBIO achieves a -32.90% return, which is significantly lower than SPY's 27.04% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
BBIO vs. SPY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and SPDR S&P 500 ETF (SPY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BBIO vs. SPY - Dividend Comparison
BBIO has not paid dividends to shareholders, while SPY's dividend yield for the trailing twelve months is around 1.17%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BBIO BridgeBio Pharma, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
SPY SPDR S&P 500 ETF | 1.17% | 1.40% | 1.65% | 1.20% | 1.52% | 1.75% | 2.04% | 1.80% | 2.03% | 2.06% | 1.87% | 1.81% |
Drawdowns
BBIO vs. SPY - Drawdown Comparison
The maximum BBIO drawdown since its inception was -92.80%, which is greater than SPY's maximum drawdown of -55.19%. Use the drawdown chart below to compare losses from any high point for BBIO and SPY. For additional features, visit the drawdowns tool.
Volatility
BBIO vs. SPY - Volatility Comparison
BridgeBio Pharma, Inc. (BBIO) has a higher volatility of 13.01% compared to SPDR S&P 500 ETF (SPY) at 3.95%. This indicates that BBIO's price experiences larger fluctuations and is considered to be riskier than SPY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.